Clinical Trial Update: Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and effectiveness of TFV 1% Gel, TDF tablets, and FTC/TDF tablets for HIV prevention in women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• FTC/TDF Tablets (emtricitabine/tenofovir disoproxil fumarate tablets)
• TDF Tablets (tenofovir disoproxil fumarate tablets)
• TFV 1% Gel (tenofovir disoproxil fumarate gel)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2016-02-10